Single Cell Technology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Single Cell Technology is a private, pre-revenue biotech firm founded in 2015, specializing in a proprietary antibody discovery platform. The company's AbTheneum™ platform is designed to overcome the limitations of conventional techniques by capturing all available data from single cells, promising faster discovery of high-quality leads, even for challenging targets. Operating as a platform/service provider, it targets the growing demand for efficient therapeutic and diagnostic antibody development but faces risks from competition and the need to validate its novel technology.

Antibodies

Technology Platform

AbTheneum™ Antibody Discovery Platform: A proprietary single-cell technology designed to capture comprehensive data for antibody discovery, positioning itself as an alternative to hybridoma and phage display. It emphasizes high-throughput, data-rich analysis without manual cell picking or surface-based spreading.

Opportunities

The global antibody discovery market is large and growing, driven by demand for new therapeutics and diagnostics.

The company's platform addresses key inefficiencies in traditional methods, offering a potential speed and quality advantage.

Successfully validating and partnering its technology could position it as a high-value service provider in a critical biopharma niche.

Risk Factors

The core technology is unproven against established and emerging competitors, creating validation risk.

As a private, pre-revenue platform company, it faces significant funding and business development execution risks.

Failure to secure partnerships or demonstrate superior outcomes would threaten its viability.

Competitive Landscape

The antibody discovery field is highly competitive, with entrenched methods (hybridoma, phage/yeast display) and numerous companies offering single-cell analysis platforms and services. Single Cell Technology must differentiate its AbTheneum™ platform on metrics like throughput, data depth, success rate on difficult targets, and cost to gain market traction.

More companies in Biologics / Biosimilars →More companies in United States →